Emergent BioSolutions | EBS - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Akebia Therapeutics USD 27.38M 5.24M 2026-03
ALKERMES USD 1.81B 57.02M 2026-06
Alnylam Pharmaceuticals USD 1.35B 278.74M 2026-06
Amarin USD 443.62M 5.8M 2026-06
ANI Pharmaceuticals USD 562.3M 21.58M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Emergent BioSolutions USD 649.3M 47.9M 2023-12
Exelixis USD 1.94B 225.57M 2026-03
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Heron Therapeutics USD 9.14M 4.15M 2026-03
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Ironwood Pharmaceuticals USD -217.14M 44.69M 2026-03
Lexicon Pharmaceuticals USD 202.86M 95.32M 2026-03
Lonza CHF 9.13B 513M 2025-12
Merck USD 45.88B 6.73B 2026-03
Moderna USD 6.76B 647M 2026-06
Myriad Genetics USD 303.9M 33.5M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pacira USD 671.98M 18.08M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD -165.36M 15.1M 2026-06
Sanofi EUR 69.57B 3.24B 2026-06
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD 327.19M 138.81M 2025-12